Global Pharmaceutical One-Material Blisters (OMB) Market Strategic Research Report

Scope of the Report

The global Pharmaceutical One-Material Blisters (OMB) market size is predicted to grow from US$ 484 million in 2025 to US$ 848 million in 2032; it is expected to grow at a CAGR of 8.3% from 2026 to 2032.

Pharmaceutical One-Material Blisters (OMB) are unit-dose pharmaceutical packaging systems in which the blister-forming web and compatible lidding material are primarily made from the same polymer or are designed to enter the same material recycling stream. These blisters are mainly used for tablets, hard capsules, softgel capsules, lozenges, and other solid dosage forms, with cavities typically produced by thermoforming and sealed using push-through, peelable, or peel-push lidding materials. Commercial OMB structures are primarily based on PET, PP, PE, and, for higher-barrier applications, COC. In addition to improving recyclability and reducing dependence on conventional multi-material structures such as PVC–aluminum and cold-form aluminum blisters, pharmaceutical OMB solutions must meet strict requirements for moisture and oxygen barrier performance, seal integrity, drug compatibility, mechanical strength, machinability, patient accessibility, shelf-life protection, and regulatory compliance.

Key Findings

Global shipment volume reached approximately 36,154 MT in 2025

Average global selling price reached US$13 per kg in 2025

PET remains the broadest commercially available material platform

Tablets and hard capsules dominate pharmaceutical blister demand

Europe leads regulatory driven qualification and early commercialization

Supplier partnerships remain central to complete system commercialization

Market Trends

The market is shifting from conventional PVC–aluminum and multilayer barrier structures toward PET, PP and other polymer systems engineered for a single recycling stream. Product development is increasingly focused on transparent polymer lidding, improved push-through performance, wider forming and sealing windows, uniform residual wall thickness after thermoforming and compatibility with existing high-speed packaging equipment. PET has developed the broadest commercial partnership network: Huhtamaki’s mono-PET Push Tab lidding is paired with Klöckner Pentaplast’s kpNext R1 forming web, while PAXXUS supplies an alternative all-polyester pharmaceutical lid for the same forming-film platform. PP is gaining strategic importance because its moisture barrier is inherent to the polymer and can be retained across the thermoformed cavity wall; SÜDPACK, Liveo Research and TekniPlex have each developed PP or PP-stream-compatible systems. PE remains a more concentrated route represented by Amcor’s AmSky family, while COC supports medium-to-high barrier applications. The long-term direction is toward validated total-pack systems, third-party recyclability certification, lower material weight, aluminum and PVC reduction, mass-balance or recycled-content options and closer collaboration among resin producers, film converters, lidding suppliers, machinery companies and pharmaceutical customers.

Market Dynamics

Drivers

Sustainability commitments by pharmaceutical companies and evolving packaging policy are the principal market drivers. Regulation (EU) 2025/40 introduces lifecycle requirements covering packaging sustainability, minimization, labelling and waste management, creating a strong design signal for recyclable packaging even where pharmaceutical immediate packaging receives differentiated treatment to protect medicine quality and security of supply. At the customer level, OMB allows drug owners to reduce PVC and aluminum consumption, improve packaging carbon profiles and demonstrate progress toward circular-packaging objectives. Adoption is also supported by solutions that can run on existing blister lines without significant tooling changes or speed reductions, reducing the capital required for qualification. The commercialization of complete bottom-web and lidding combinations further lowers technical risk, while successful deployment in branded OTC products demonstrates that mono-material systems can move beyond laboratory trials into large-scale pharmaceutical use.

Restraints

The principal restraint is the technical and regulatory burden associated with replacing a validated primary pharmaceutical package. Standard PET structures generally provide lower moisture protection than PP, COC, PVdC-coated films or cold-form aluminum, limiting immediate conversion for highly hygroscopic drugs. Higher barrier performance can require specialty polymers, barrier layers or modified sealing systems, increasing material cost and complicating recycling claims. Each packaging change may require drug–package compatibility testing, seal-integrity verification, transportation testing, accelerated and long-term stability studies, equipment trials and regulatory documentation. India’s Drugs Rules require pharmaceutical packaging materials to comply with defined specifications and to be compatible with the drugs they contain, while China’s NMPA associated-review framework requires drug-packaging-material information and relevant changes to be maintained and evaluated with the finished medicine. Long validation cycles, conservative risk management and the possibility of requalification across multiple countries therefore slow conversion of established products.

Opportunities

The most attractive opportunity is the development of higher-barrier PP and COC systems capable of replacing selected PVC–PVdC, PVC–PCTFE and cold-form aluminum applications while remaining compatible with conventional form-fill-seal equipment. Additional opportunities include transparent aluminum-free packs, child-resistant and senior-friendly opening structures, thinner forming webs, printable polymer lids and systems incorporating chemically recycled or mass-balance resin. Export-oriented pharmaceutical manufacturers in India and China represent an important qualification pool because packaging for European and North American markets is increasingly assessed against sustainability and material-efficiency criteria. OTC medicines, generic tablets, vitamins and dietary supplements offer earlier conversion potential because many products have moderate barrier requirements and faster packaging-development cycles. Japan also presents an emerging development opportunity: KANAe has introduced a development-stage polyolefin PTP system evaluated for the PP recycling stream and designed for use on an existing packaging machine, indicating scope for localized material-and-machinery co-development.

Challenges

Manufacturers must balance recyclability with pharmaceutical safety, shelf-life protection and patient usability. A package described as one-material may still contain inks, coatings, sealants or functional layers that affect its acceptance in a specific recycling system. Collection and sorting infrastructure also varies significantly by country, meaning that technical recyclability does not automatically result in recycling at scale. Thermoforming redistributes film thickness, so barrier performance at the thinnest cavity areas must remain consistent across production speeds, tooling geometries and material batches. Lidding films must deliver reliable sealing while maintaining controlled push-through or peel forces, print quality and resistance to transport damage. Commercial risks include resin-price volatility, low early-stage production volumes, extended customer testing, uncertain pharmaceutical change timelines and the possibility that existing PVC or aluminum structures remain economically preferable for high-barrier products. Suppliers therefore need robust application laboratories, machine-testing capabilities, pharmaceutical quality systems and long-term technical support rather than relying solely on an environmental value proposition.

Industry Chain Analysis

The upstream industry comprises pharmaceutical-grade PET, PP, PE and COC resins, functional additives, heat-seal materials, barrier technologies, printing inks, coating chemicals and extrusion or thermoforming equipment. Midstream companies manufacture rigid forming webs, flexible or semi-rigid lidding films and complete matched blister systems through extrusion, coextrusion, coating, scoring, printing and slitting. Additional value is created through barrier testing, residual-wall-thickness analysis, sealing-window optimization, machine trials, stability support, recyclability assessment and regulatory documentation. Downstream customers include branded pharmaceutical companies, generic-drug manufacturers, CDMOs, contract packagers and nutraceutical producers. Resin suppliers and blister machinery manufacturers are important enabling participants but belong to different revenue pools from finished OMB film and complete-system suppliers. The highest-value capabilities are proprietary material formulation, validated forming-and-lidding combinations, cleanroom manufacturing, consistency between production batches and the ability to support pharmaceutical customers through qualification and post-approval packaging changes.

Segment Insights

PET Material is expected to remain the largest segment over the near term because it has the broadest base of commercially available forming webs and lidding materials. Klöckner Pentaplast supplies mono-PET bottom web, Huhtamaki and PAXXUS provide complementary PET lidding solutions, and Liveo Research, TekniPlex and Hysum Flexibles offer additional PET-based products or complete systems. The platform benefits from optical clarity, thermoformability, established material identification and the availability of push-through and peelable lid formats. PP Material is positioned as the key higher-growth platform because it offers stronger inherent moisture resistance and supports complete forming-and-lidding systems from SÜDPACK, Liveo Research and TekniPlex. The report’s Others segment should cover PE and COC rather than treating them as undefined residual products: PE is represented by recycle-ready thermoformed systems such as AmSky, while COC targets medium-to-high moisture-barrier applications and commands a higher material cost. This three-part segmentation—PET Material, PP Material and Others—therefore remains practical and mutually exclusive for market measurement.

Downstream Market Opportunities

Tablets represent the largest addressable application because they are extensively packaged in push-through unit-dose formats and can be accommodated by standardized cavity geometries. Hard capsules form the second major application and require deeper cavities, stable thermoforming and reliable protection against moisture. The Others category covers softgel capsules, lozenges and other solid-dose products where cavity design, chemical compatibility or opening performance differs from standard tablets. Early adoption is most likely in OTC drugs, generic medicines and nutraceutical products with low-to-medium barrier requirements, while moisture-sensitive prescription drugs offer higher-value opportunities for advanced PP and COC structures after stability validation. CDMOs and contract packagers are strategically important because a qualified material platform can be applied across multiple customers, formulations and regional product launches.

Regional Insights

Europe is the leading market for product development, qualification and early commercialization, supported by a concentrated pharmaceutical-packaging industry and a regulatory direction that emphasizes packaging minimization, circularity and improved waste management. Germany, Switzerland, the United Kingdom and neighboring converting hubs host many of the current OMB technology and partnership leaders. India offers significant long-term potential through its large generic-drug and export-manufacturing base, but adoption remains sensitive to material cost, existing line performance and the documentation required for primary-packaging changes under CDSCO rules. Export-oriented manufacturers and newly approved products are likely to adopt first. China combines a broad pharmaceutical-packaging supply chain with increasing interest in recyclable materials, and Hysum Flexibles has established a local APET forming-web and lidding platform. However, NMPA associated review and change-management requirements make pharmaceutical validation, registration support and stable domestic supply decisive competitive factors.

This report presents a comprehensive overview of the global Pharmaceutical One-Material Blisters (OMB) market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• PET Material
• PP Material
• Others

Segment by Opening Mechanism

• Push-Through Blisters
• Peelable Blisters
• Other

Segment by Forming-Web Thickness

• Thin-Gauge: ≤249 μm
• Standard-Gauge: 249–359 μm
• Thick-Gauge: ≥359 μm

Segment by Application

• Tablets
• Hard Capsules
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Pharmaceutical One-Material Blisters (OMB) market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Tablets, Hard Capsules, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact